1. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-73. 
2. Sabry M, Al-Hendy A. Medical treatment of uterine leiomyoma. Reprod Sci. 2012;19(4):339-53. 
3. Parker WH. Uterine myomas: management. Fertil Steril. 2007;88(2):255-71. 
4. Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):135-40. 
5. Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):655-76. 
6. Trefoux Bourdet A, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. Int J Womens Health. 2015;7:321-30. 
7. Ribič-Pucelj M, Tomaževič T, Vogler A. Laparoskopska miomektomija. In: Ribič-Pucelj M, Pegan V, Pašić RP. Endoskopske operacije v ginekologiji. Radovljica: Didakta; 2007. pp. 207-15. 
8. Brun JL, Rajaonarison J, Froeliger A, Monseau-Thiburce AC, Randriamboavonjy R, Vogler A. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy. Eur J Obstet Gynecol Reprod Biol. 2018;222:13-8. 
9. Sinai Talaulikar V, Belli AM, Manyonda I. GnRH agonists: do they have a place in the modern management of fibroid disease? J Obstet Gynaecol India. 2012;62(5):506-10. 
10. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109(10):1097-108. 
11. Mavrelos D, Ben-Nagi J, Davies A, Lee C, Salim R, Jurkovic D. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial. Hum Reprod. 2010;25(9):2264-9. 
12. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al.; PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565-73.e1. 
13. Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165-173.e4. 
14. Powell M, Dutta D. Esmya ® and the PEARL studies: A review. Womens Health (Lond). 2016;12(6):544-8. 
15. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-32. 
16. Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014;8:285-92. 
17. Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947-53. 
18. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556-69. 
19. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-20. 
20. Sabry M, Al-Hendy A. Innovative oral treatments of uterine leiomyoma. Obstet Gynecol Int. 2012;2012:943635. 
21. Duhan N. Current and emerging treatments for uterine myoma - an update. Int J Womens Health. 2011;3(1):231-41. 
22. Ginsburg ES, Benson CB, Garfield JM, Gleason RE, Friedman AJ. The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study. Fertil Steril. 1993;60(6):956-62. 
23. Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S. Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study. Eur J Obstet Gynecol Reprod Biol. 2014;181:157-62. 
24. Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HJ, Zatik J, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519-27.e3. 
25. Rabe T, Ahrendt HJ, Albring C, Bitzer J, Bouchard P, Cirkel U, et al. Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea: joint statement by the german society for gynecological endocrinology and reproductive medicine (DGGEF) and the german professional association of gynecologist (BVF). J Reproduktionsmed Endokrinol. 2013;10(Special Issue 1):82-101. 
26. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396-407. 
27. European medicines agency. Science medicines health. Esmya (ulipristalacetat). Available from: http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Summary_for_the_public/human/002041/WC500124089.pdf 
28. European medicines agency. Science medicines health. Priloga 1. Povzetek glavnih značilnosti zdravila. Available from: http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Product_Information/human/002041/WC500124085.pdf 
29. European medicines agency. Science medicines health. PAssessment report on provisional measures. Available from: https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-assessment-report-provisional-measures_en.pdf 
30. Luyckx M, Squifflet JL, Jadoul P, Votino R, Dolmans MM, Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014;102(5):1404-9. 
31. Monleón J, Martínez-Varea A, Galliano D, Pellicer A. Successful pregnancy after treatment with ulipristal acetate for uterine fibroids. Case Rep Obstet Gynecol. 2014;2014:314587. 
32. Murad K. Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid. J Obstet Gynaecol Can. 2016;38(1):75-9. 
